Johnson & Johnson takes another hit
This time, the problem isn't with Tylenol but with its delivery method.
The company is recalling 574,000 bottles of grape-flavored Tylenol for children younger than 2 years old. You can read more about the recall here.
There's nothing wrong with the medicine. The problem is with the new system whereby parents stick a plastic dosing syringe into a small hole to draw out the liquid Tylenol. About 17 parents or caregivers complained that when they inserted the syringe, the doughnut-shaped cover fell into the bottle.
And that began yet another recall for Johnson & Johnson's McNeil Consumer Healthcare division, which has suffered 25 product recalls since 2009. Among the recalls were versions of Tylenol, Motrin, Benadryl and Zyrtec.
Johnson & Johnson's manufacturing process came under intense scrutiny from Congress, regulatory agencies and parents. The Food & Drug Administration told parents to stop using the products and mentioned concerns over "tiny particles" in them and inactive ingredients that may not have met quality standards. Health regulators took over supervision of three of J&J's manufacturing plants.
Parents fled the brand. Pediatricians began recommending generic products. It was an absolute disaster for a company that built a reputation as a reliable provider of health and consumer products. McNeil's U.S. sales plummeted to $1.4 billion last year, less than half of the $3.1 billion seen in 2008, The Wall Street Journal reports.
Many Tylenol products have been off the shelves for at least a year. The new infant Tylenol was just returned to the market in November, and now there's no telling when it will come back.
The troubles in the McNeil division are far from over. In fact, a few weeks ago the company replaced the top two lieutenants it had put in charge of turning the unit around. One of those leaving was just put in charge of McNeil last April.
The problems at McNeil are one reason Johnson & Johnson's 2011 profit fell to $9.7 billion from $13.3 billion in 2010. Sales rose 5.6% to $65 billion, but nearly across the board, U.S. sales were in decline, while international sales rose.
McNeil is just a small part of Johnson & Johnson, however. The company's pharmaceutical sales rose to a whopping $24 billion last year, while its medical devices and diagnostics unit saw sales rise to nearly $26 billion.
Still, analysts are concerned about the company's coming year, and many slashed expectations for 2012 after Johnson & Johnson disappointed investors with its forecast for earnings of between $5.05 and $5.15 per share. Analysts were expecting $5.21.
Investors had hoped this was the year that Johnson & Johnson could clean up McNeil and re-introduce Tylenol as a brand consumers could trust. The latest recall puts a dent in those hopes.
Could it possibly have been caused by the fact that the article states that, "Health regulators took over supervision of three of J&J's manufacturing plants." They would be GOVERNMENT Health Care Regulators, would they not?. Just wait until they take over "SUPERVISING" the rest of the health care industry!
Kim....Bottom line,any Company that has 25 recalls in 2 years....Needs to get BIT and bit hard.
When and if, it comes to Children....The division should be shut down.
And I'm just an old Grandpa and G-Grampa.
You will realize what I'm talking about......Some Day.
MORE ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The Fed may start tapering in just a few months. Here are a few of the likely winners and losers.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.